长期与短期双联抗血小板治疗在急性冠脉综合征患者中与较低死亡、卒中或梗死风险相似相关,无论是否存在基础肾脏病
本研究为观察性前瞻性多中心队列研究,纳入SWEDEHEART注册的36001例急性冠脉综合征患者,比较氯吡格雷联合阿司匹林的双联抗血小板治疗(DAPT)延长超过3个月与3个月时停止DAPT的结局。结果显示,延长DAPT与各慢性肾脏病(CKD)分层中死亡、心肌梗死或缺血性卒中的复合结局风险降低相关,但出血一般更常见,且DAPT时长与CKD分层之间无交互作用。
要点
- 延长DAPT超过3个月与各CKD分层中死亡、心肌梗死或缺血性卒中的复合结局风险降低相关。
- 延长DAPT组中各CKD分层的出血一般更常见。
- DAPT时长与CKD分层之间对所有研究结局均无交互作用。
核心结论
- 与3个月DAPT相比,延长DAPT与较低死亡、卒中或再梗死风险相似相关,无论是否存在基础CKD。
研究设计与样本
- 观察性、前瞻性、多中心队列研究,纳入SWEDEHEART注册的36001例连续急性冠脉综合征且已知血清肌酐的患者。
- 暴露为3个月后延长DAPT对比3个月时停止DAPT,DAPT时长通过氯吡格雷和阿司匹林的配发片剂评估,CKD分期按估算肾小球滤过率(eGFR)分类。
主要发现
- 主要结局(死亡、心肌梗死或缺血性卒中的复合结局)在eGFR>60组调整风险比(95%CI)为0.76(0.67-0.85),eGFR≤60组为0.84(0.73-0.96)。
- eGFR 45-60组调整风险比为0.85(0.70-1.05),eGFR 30-45组为0.78(0.62-0.97),eGFR≤30 ml/min/1.73 m2组为0.93(0.70-1.24)。
- 出血结局在延长DAPT组中各CKD分层一般更常见。
- 聚合结局分析在各CKD分层中同样支持延长DAPT。
- DAPT时长与CKD分层之间对所有研究结局均无交互作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD). To study this, we performed an observational, prospective, multicenter cohort study of 36,001 patients of the SWEDEHEART registry. The exposure was DAPT prolonged after 3 months versus DAPT stopped at 3 months in consecutive patients with acute coronary syndrome and known serum creatinine. DAPT duration with clopidogrel and aspirin was assessed by dispensed tablets. CKD stages were classified according to estimated glomerular filtration rate (eGFR). Study outcomes were 1) the composite of death, myocardial infarction, or ischemic stroke; 2) bleeding; or 3) the aggregate of these two outcomes within day 111 and 365 from discharge. A longer DAPT duration, as compared with 3-month DAPT, was associated with lower hazard ratios for outcome one in each CKD stratum (eGFR over 60, adjusted hazard ratio [95% confidence interval] 0.76 [0.67-0.85]; eGFR 60 and less, 0.84 [0.73-0.96], of which eGFR between 45 and 60, 0.85 [0.70-1.05], eGFR between 30 and 45, 0.78 [0.62-0.97]; eGFR 30 and less ml/min/1.73 m2, 0.93 [0.70-1.24]. Bleeding (outcome 2) was in general more common in the longer DAPT group of each aforementioned CKD stratum. Aggregated outcome analysis (outcome 3) similarly favored longer DAPT in each stratum. There was no interaction between DAPT duration and CKD strata for any of the study outcomes. Thus, a prolonged as compared with three-month DAPT was similarly associated with a lower risk of death, stroke, or reinfarction regardless of underlying CKD.
引用
- Carrero JJ, Varenhorst C, Jensevik K, et al. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney Int. 2016. PMID: 27865441. doi:10.1016/j.kint.2016.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。